Eli Lilly’s stock soars as Mounjaro, Zepbound sales lead to a big profit beat

By / / Finance / 1 minute of reading



im 656195
Eli Lilly’s stock was headed for its best day in a year on Thursday, after the drugmaker reported second-quarter earnings that rose well above forecasts, amid strength in sales of its diabetes and obesity treatments, Mounjaro and Zepbound.



Source link

About The Author

Avatar of Shana Hull
Shana Hull is a professional writer, editor, and interviewer. She's written for a variety of publications in the arts, construction, automotive, travel, real estate, and fashion industries. Shana has also worked as a content strategist for several companies in the finance and technology sectors.

Start typing and press enter to search

Scroll to Top